2/10
08:30 am
help
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Low
Report
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
2/10
07:56 am
help
Helus Pharma appoints Michael Cola as CEO [Seeking Alpha]
Low
Report
Helus Pharma appoints Michael Cola as CEO [Seeking Alpha]
2/10
07:30 am
help
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Low
Report
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
2/2
07:00 am
help
Cybin (NASDAQ:HELP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.
Medium
Report
Cybin (NASDAQ:HELP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.
1/10
03:22 pm
help
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq [Yahoo! Finance]
Low
Report
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq [Yahoo! Finance]
1/5
08:04 am
help
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq [Yahoo! Finance]
High
Report
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq [Yahoo! Finance]
1/5
07:30 am
help
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
High
Report
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq